Arnold Eugene Postlethwaite, MD, AB...1966-1967 Medicine Internship, Tulane Division, Charity...

Postlethwaite CV

10/18/2016

of 26

CURRICULUM VITAE

Arnold Eugene Postlethwaite, MD, AB Goodman Chair of Excellence Professor in Medicine

Director, Division of Connective Tissue Diseases

The University of Tennessee Health Science Center, Memphis, Tennessee

https://academic.uthsc.edu/faculty/Arnold_E_Postlethwaite.html

Citizenship: United States of America

Telephone: Business (901) 448-5774

EDUCATION

1962 AB, West Virginia University, Morgantown, West Virginia

1966 MD, Weill Medical College, Cornell University Medical College, New York, New York

PROFESSIONAL EXPERIENCE

1966-1967 Medicine Internship, Tulane Division, Charity Hospital, New Orleans, Louisiana

1967-1968 Junior Assistant Resident, Tulane Division, Charity Hospital, New Orleans, Louisiana

1968-1969 Captain, U.S. Army Medical Corps Battalion Surgeon, 11th Armored Cavalry Regiment (Colonel

George Patton IV, Regimental Commander) and Commanding Officer 541st Medical Dispensary,

Republic of South Vietnam

1969-1970 Major, U.S. Army Medical Corps, Chief Medical Officer, Armed Forces Examining and Entrance

Station, Richmond, Virginia

1970-1971 Clinical Fellow, Rheumatic and Genetic Diseases, Duke University Medical Center, Durham,

North Carolina (W. M. Kelley, MD, Division Chief)

1971-1972 Senior Assistant Resident, Department of Medicine, Duke University Medical Center, Durham,

North Carolina

1972-1973 Research Fellow (Research Training Program), Division of Rheumatic and Genetic Diseases,

Duke University Medical Center, Durham, North Carolina (Ralph Snyderman, MD, Sponsor)

1973-1976 Assistant Professor, Department of Medicine, University of Tennessee Health Science Center,

Memphis, Tennessee and Research Associate, Veterans Administration Medical Center, Memphis,

Tennessee

1976-1977 Research Associate, Veterans Administration Medical Center, Memphis, Tennessee

1976-1982 Associate Professor, Department of Medicine, University of Tennessee Health Science Center,

Memphis, Tennessee and Research Associate, Veterans Administration Medical Center, Memphis,

Tennessee

1978-1980 Clinical Investigator, Veterans Administration Medical Center, Memphis, Tennessee

1981-1986 Chief, Rheumatology Section, Veterans Administration Medical Center, Memphis, Tennessee

1982- Professor with Tenure, Department of Medicine, University of Tennessee Health Science Center,

Memphis, Tennessee

1984- Director, Division of Connective Tissue Diseases, Department of Medicine, University of

Tennessee Health Science Center, Memphis, Tennessee

2004- Goodman Chair of Excellence Professor in Medicine, University of Tennessee Health Science

Center, Memphis, Tennessee

BOARD CERTIFICATION

1967 Certified by Louisiana State Board of Medical Examiners

1967 Diplomate of the National Board of Medical Examiners

https://academic.uthsc.edu/faculty/Arnold_E_Postlethwaite.html

Postlethwaite CV

10/18/2016

of 26

1974 Diplomate of the American Board of Internal Medicine

1976 Subspecialty Certification in Rheumatology

PROFESSIONAL SOCIETIES

1972 American Rheumatism Association

1978 American Association for the Advancement of Science

1978 Southern Society for Clinical Investigation

1972 American Federation for Clinical Research

1976 Sigma Xi

1977 American Association of Immunologists

1977 Central Society for Clinical Research

1982 American Society for Clinical Investigation

HONORS AND AWARDS

Doctor of the Year Award, Scleroderma Foundation, Washington, DC, March 2003

Master, American College of Rheumatology, 2006-present

President’s Award, Tennessee Rheumatology Society Meeting, Nashville, Tennessee, May 19, 2012

Doctor of the Year Award, Scleroderma Foundation, Gaylord, Texas, July 27, 2012

GRANT SUPPORT (Current and Past)

Support by Grants on which I am Principal Investigator or Program Director or Co-Investigator:

PENDING GRANTS

Active Grants Note: VA Merit Grant approval as of June 2016 with 4.6% rate

VA R01 Clinical Merit Grant (1I01 CX001400-01A2) (PI: Arnold Postlethwaite) 10/01/2016 – 09/30/2020

Department of Veterans Affairs

Title: “The Vitamin D-Gelsolin-S1P Axis in Rheumatoid Arthritis”

Goal: This grant will explore interactions between vitamin D status, plasma gelsolin, and plasma sphingosine

1-phosphate, which have independently been described as influencing severity of arthritis in patients with

rheumatoid arthritis (RA), and determine whether a model that includes measurement of all three is a better

correlate of RA disease severity than either does alone.

Annual Direct Costs: $199,778.00 1st year ($150,000.00 Y2-5)

NIH/NIAMSD 1R21 AR066505-01A1 (Slominski) 9/18/14 – 8/31/16

“Mechanism of Action of 20-Hydroxyvitamin D3 in Dermal Fibroblasts”

Goal: To determine the mechanism of action in 20(OH)D3 that would prove to be a treatment of scleroderma

and hyperproliferative skin disorders

Annual Direct Cost: $132,000

Postlethwaite CV

10/18/2016

of 26

VA Program Project 51PIBX001607-04 (PI: John Stuart) 10/01/12 – 9/30/2016

“Program Project for Mechanisms and Treatment of Arthritis” VA Program Project 1IPIBX001607-01,

Project 3: PI-Arnold E. Postlethwaite, MD 10/01/12 – 12/31/15

Title: “Suppression of Arthritis by 20(OH)D3”

Goal: The major goals of this project are to study the classical and passive type II antibody-induced collagen-

induced arthritis models in mice focusing on the role of sphingosine-1 phosphate in mediating effects of

20(OH)D3.

Annual Direct Costs: $87,050 1st yr

Past Grants (Since 2001) NIH/NIAMS 2R01 AR052190-07 (MPI) (Postlethwaite) 09/25/13 – 10/25/14

“Novel Biosynthetic Pathway for Secosteroids in the Skin” (no cost extension 10/31/15)

(Contact MPI: Slominski)

Goal: To determine optimal oral dose of 20(OH)D3 and 17,20(OH)2pD in treating mouse scleroderma models.

Annual Direct Costs: $200,000.

VA Merit Review Grant (101BX000671) 10/01/11 – 09/30/15

Principal Investigator: Weikuan Gu; Co-Investigator: Postlethwaite

“Study of the Genetic Basis for Fibrotic Diseases in a Mouse Model”

Goal: The aim of this project is to study genetic factors that regulate fibrosis in dermal tissues using a mouse

autoimmune disease model called Tight Skin 2 (Tsk2).

Annual Direct Costs: $220,000

VA Clinical Merit Review Award #IMMA-007-08S 10/01/09 – 09/30/14 (no cost extension till 09/30/15)

PI: Postlethwaite

“Phase I Trial of Oral Altered Peptide Ligand (CII APL) A12 in Patients with Rheumatoid Arthritis” Goal: To enroll 40 patients with active RA in four treatment arms, placebo, APL 12 @ 30µg/d, 100µg/d, and

1,000µg/d in a single site trial to determine therapeutic value of APL.

Annual Direct Costs: $150,000. Total Amount Requested: $750,000

NIH/NIAMS 1R21 AR063242-01A1 04/1/13 – 03/31/15

Principal Investigators: Wei Lei and Duane D. Miller; Co-Investigator: Postlethwaite

“Discovery of Tissue-Selective, Nonhypercalcemic VDR Modulators for RA Treatment”

Goal: The major goal of this project is to develop tissue-selective, non-hypercalcemic vitamin D receptor

modulators as a potentially more effective treatment for arthritis.


Scleroderma Foundation (Postlethwaite) 01/01/10 – 12/31/11

“SSc Platelet Phenotype Effected by Cytokines” Goal: to define and determine how cytokine profiles in the circulating blood of SSc patients is associated with

platelet phenotype in an attempt to suggest treatment strategies.


Postlethwaite CV

10/18/2016

of 26

NIH Challenge Grant 5RC1AR058723-01 (Postlethwaite) 09/30/09 – 09/29/11

“Chronic Sleep Restriction Priming of the Immune Response to Autoantigen: Role of the SNS”

Goal: To assess mechanisms by which the SNS modulates immune response to type II collagen and arthritis in

mice.


VA Merit Review (Postlethwaite) 04/01/07 – 03/30/11

“Monocyte Transdifferentiation into Fibroblasts”

Goal: to determine which subsets of CD14+ monocytes transdifferentiate and mechanisms of

transdifferentiation.


NIH, N01 A105419 (Site PI: Postlethwaite) 03/03/05 – 09/21/12

“Scleroderma: Cyclophosphamide or Transplantation” SCOT Study (Duke University). UTHSC is a

Rheumatology Center.” Goal: To determine whether autologous CD34+ stem cells will improve fibrosis and survival in patients with

scleroderma.


NIH, 5T32 AR-07317-30 (Postlethwaite) 05/01/04 – 04/30/10 (No cost extension)

“Research Training in Connective Tissue Diseases”


NIH/NIAMS 1R21 AR48403-01A (Postlethwaite) 09/15/02 – 09/14/05

“Sleep Fragmentation Effects on Murine CII-Induced Arthritis

Goal: To develop a method to induce chronic fragmented sleep in mice with Type II Collagen-Induced

Arthritis.


NIH (NIAMS) 1-P50AR44890-01A2 (Postlethwaite) 08/24/01 – 06/30/06

“SCOR on the Pathogenesis of Scleroderma” Total Cost: $4,306,370

Administrative CORE


Project 1: “Outgrowth of Fibroblast-like Cells of SSc PBMC”

Goal: To determine mechanisms by which monocytes differentiate into fibroblast-like cells.


NIH (NIAMS), N01-AR-9-2242 (Postlethwaite) 09/30/99 – 04/30/06

“Multicenter Phase II Trial of Oral Type I Collagen in Scleroderma”

Annual Direct Cost: $683,250 (Total for 11 Centers)

Lead Center – University of Tennessee

Goal: Conduct a Phase II trial of oral bovine Type I collagen in patients with scleroderma.


NIH, R01-AR-45255-01 (Postlethwaite) 09/1/98 – 08/31/06

“CII Oral Tolerance Induction in RA Patients off NSAIDs”

Goal: Conduct a Phase II study of efficacy of Type II bovine collagen in patients with RA.


Postlethwaite CV

10/18/2016

of 26

NIH, Research Training in Connective Tissue Diseases 09/20/78 – 04/30/2010

Postlethwaite CV

10/18/2016

of 26

HOSPITAL APPOINTMENTS

1985- Present Attending Staff for the Regional Medical Center, Memphis, Tennessee

1973- Present Attending Staff for the Veterans Administration Medical Center, Memphis, Tennessee

1990- 2004 Associate Staff for William F. Bowld Hospital, Memphis, Tennessee (closed)

2008- Present Courtesy Staff for Methodist University Hospital, Memphis, Tennessee

SPECIAL APPOINTMENTS:

1977-1978 Councilor, Midwest Rheumatism Association

1981-1983 Member, Local Chapter Research Grant Committee, Arthritis Foundation (National)

1981-1984 Editorial Board, Lymphokine Research

1983-1986 Member, Veterans Administration Immunology Merit Review Board

1984-1989 Editorial Board, Arthritis and Rheumatism

1984-1987 Member, Scleroderma Council of the American Rheumatism Association

1986-1988 Member, Local Chapter Research Grant Committee, Arthritis Foundation (National)

1987-1989 Chairman, Scleroderma Section, Program Committee for National Scientific Meeting of The

American Rheumatism Association Meeting in Washington, D.C.

1989-1991 Member, Fellowship Subcommittee, National Arthritis Foundation

1988- Member, Medical Advisory Board, United Scleroderma Foundation

1989-1993 Member, NIH Special Grants Review Committee

1991-1995 Chairman, Cell Biology Grant Review Committee, National Arthritis Foundation

1991-1994 Chairman, Arthritis Foundation Study Section

1997-1999 Editorial Board, American Journal of Physiology

1999-2001 California Tobacco-Related Diseases Research Program

2001-2003 Chairman, NIAMS R03 Review Committee

2001 Member, National Scleroderma Foundation

2002-2005 Chairman, National Scleroderma Foundation Grant Review Committee

2002 Member, NIAMS SCOR on Women’s Health Review Committee

2002 Member, NIAMS Clinical Research Centers Review Committee

2002 Ad Hoc Reviewer for R01 Grants, National Heart, Lung, and Blood Institute

2002 Reviewer: Arthritis Foundation, Journal of Immunology, Journal of Clinical Investigation

2002-2014 Member of NIH Panels to review R03, R01, R21, Small Business Grants, P60, and P01 grants

2007-2012 Member Veterans Administration Immunology Merit Review Board

2011-2013 Co-chair of Scleroderma Abstract Selection Committee for Annual Scientific Meeting, American

College of Rheumatology

2013-2017 Member National Scleroderma Foundation Grant Review Committee

2013-2017 Member, Veterans Administration Endocrinology Merit Review Panel

PRE- AND POST-DOCTORAL TRAINEES Kanangat, S, MD 2000-2002 Post

Takagi, K, MD 2004-2005 Post

Herring, P, MD 2005-2006 Post

Walls, T, MS 2008 Pre

Brown Lobbins, ML, DO 2008-2009 Post

Radomir M. Slominski, MD, MS 10/17/2016-12/31/2016 Post, research volunteer

Postlethwaite CV

10/18/2016

of 26

BIBLIOGRAPHY

Patents

Application #: 5,436,228

Title: Chemotactic Wound Healing Peptides

Granted: 7/25/1995

Assignee: Justia

CoInventors: Andrew Kang, Jerome Seyer

URL:

https://www.google.com/patents/US5436228?dq=chemotactic+wound+patent+5436228&hl=en&sa=X&ved=0

CB0Q6AEwAGoVChM IuJyNreeLyQIVRiYmCh3VcgMM

and

http://www.freepatentsonline.com/5436228.html

Application #: 5824647

Title: Chemotactic Wound Healing Peptides

Granted: 10/20/1998

Assignee: Justia

CoInventors: Andrew Kang, Jerome Seyer

URL: http://www.google.com/patents/US5824647

Application #: 2007/0142286

Title: Methods of Treating Fibrosing Diseases by Induction of Immune Tolerance

Granted: 7/21/2007

Assignee: Justia

CoInventor: Andrew Kang

URL:

https://www.google.com/patents/US20070142286?dq=patent+0142286+kang&hl=en&sa=X&ved=0CBwQ6AE

wAGoVChMIj PDD4eeLyQIVASQmCh1qaADw

Application #: Provisional 61/080,012 and 61/104,504

Title: A Single Nucleotide Polymorphism (SNP A-1515737 AA Genotype) Associated with Resistance to Oral

Immune Tolerance Inductions

Short Title: ARG201 Therapy for Scleroderma

Granted: 7/11/2008 and 10/10/2008

Assignee: arGentis Pharmaceuticals, LLC

CoInventors: Andrew Kang, Weikuan Gu

Application #: 11/900,525 on 11/16/2006

Patent #: 7,718,765 B2


Granted: 5/18/2010

Assignee: UTRF


https://www.google.com/patents/US5436228?dq=chemotactic+wound+patent+5436228&hl=en&sa=X&ved=0CB0Q6AEwAGoVChM%20IuJyNreeLyQIVRiYmCh3VcgMM

https://www.google.com/patents/US5436228?dq=chemotactic+wound+patent+5436228&hl=en&sa=X&ved=0CB0Q6AEwAGoVChM%20IuJyNreeLyQIVRiYmCh3VcgMM

http://www.freepatentsonline.com/5436228.html

http://www.google.com/patents/US5824647

https://www.google.com/patents/US20070142286?dq=patent+0142286+kang&hl=en&sa=X&ved=0CBwQ6AEwAGoVChMIj%20PDD4eeLyQIVASQmCh1qaADw

https://www.google.com/patents/US20070142286?dq=patent+0142286+kang&hl=en&sa=X&ved=0CBwQ6AEwAGoVChMIj%20PDD4eeLyQIVASQmCh1qaADw

Postlethwaite CV

10/18/2016

of 26

Application #: 14/106,038 on 12/13/2013


Granted: pending

Assignee: UTRF


Application #: 14/043,444 issued 10/1/2013 (continuation of Application 12/914,823 filed 10/28/2010 and

provisional application 61/244,627 issued 10/28/2009) and Patent 9,144,595 B2

Title: Altered Peptide Ligands for Treatment of Rheumatoid Arthritis

Short Title: APLS for Treating Arthritis

Granted: 9/29/15; announced 2/3/2016

Assignee: UTRF / arGentis Pharmaceuticals, LLC

CoInventors: Andrew Kang, Linda Myers

URL: http://www.patentbuddy.com/Patent/9144595

http://www.patentbuddy.com/Patent/9144595

Postlethwaite CV

10/18/2016

of 26

Publications: Original Articles (most recent to earliest)

1. Skobowiat C, Postlethwaite AE, Slominski AT. Skin exposure to ultraviolet B rapidly activates systemic

neuroendocrine and immunosuppressive responses. Photochem Photobiol. 2016 Sept 25. doi:

10.1111/php.12642. [Epub ahead of print]. PMID: 27716949.

2. Schlabritz-Loutsevich NE, Comuzzie AG, Mahaney MM, Hubbard GB, Dick EJ Jr, Kocak M, Gupta S,

Carrillo M, Schenone M, Postlethwaite A, Slominski A. Serum vitamin D concentrations in baboons

(papio spp.) during pregnancy and obesity. Comp Med [Internet]. 2016 Apr;66(2):137-42. PMID:

27053568. PMCID: PMC4825963. Available from: www.scopus.com

3. Lin Z, Marepally SR, Kim TK, Janjetovic Z, Oak AS, Postlethwaite AE, Myers LK, Tuckey RC,

Slominski AT, Miller DD, Li W. Design, synthesis and biological activities of novel gemini 20S-

hydroxyvitamin D3 analogs. Anticancer Res. 2016 Mar;36(3):877-86. PMID: 26976974.

4. Slominski AT, Kim T-K, Li W, Postlethwaite A, Tieu EW, Tang EKY, Tuckey RC. Detection of novel

CYP11A1-derived secosteroids in the human epidermis and serum and pig adrenal gland. Sci Rep. 2015

Oct;5(1):art. no 14875. doi: 10.1038/srep14875. PMID: 26445902. PMCID: 4597207.

5. Jiao Y, Chen H, Gu T, Wang L, Postlethwaite A, Gu W. Molecular network of important genes for

systemic sclerosis-related progressive lung fibrosis. BMC Res Notes. 2015 Oct 7;8:544. doi:

10.1186/s13104-1510-4. PMID: 26444860.

6. Lin Z, Marepally SR, Ma D, Myers LK, Postlethwaite AE, Tuckey RC, Cheng CY, Kim T-K, Yue J,

Slominski AT, Miller DD, Li W. Chemical synthesis and biological activities of 20S,24S/R-

dihydroxyvitamin D3 epimers and their 1α-hydroxyl derivatives. J Med Chem. 2015 Oct 8;58(19):7881-

7. doi: 10.1021/acs.jmedchem.5b00881. PMID: 26367019 PMCID: 4613797.

7. Wang L, Liu H, Jiao Y, Wang E, Clark SH, Postlethwaite AE, Gu W, Chen H. Differences between mice

and humans in regulation and the molecular network of collagen, type III, alpha-1 at the gene expression

level: Obstacles that translational research must overcome. Int J Mol Sci. 2015 Jul 3;16(7):15031-56. doi:

10.3390/ijms160715031. PMID: 26151842. PMCID: PMC4519886.

8. Slominski A, Postlethwaite AE. Skin under the sun: When melanin pigment meets vitamin D. Endocrinol.

2015 Jan;156(1):1-4. doi: 10.1210/en.2014-1918. PMID: 25526548.

9. Sun S, Jiao Y, Wei W, Postlethwaite AE, Gu W, Sun D. Comparison of LAIR-1 genetic pathways in

murine vs human internal organs. Gene. 2014 Sep 16;552(1):140-5. pii: S0378-1119(14)01053-1. doi:

10.1016/ j.gene. 2014.09.027. PMID: 25234728.

10. Chen J, Wang J, Kim TK, Tieu EW, Tang EK, Lin Z, Kovacic D, Miller DDE, Postlethwaite A, Tuckey

RC, Slominski AT, Li W. Novel vitamin D analogs as potential therapeutics: metabolism, toxicity

profiling, and antiproliferative activity. Anticancer Res. 2014 May;34(5):2153-63. PMID: 24778017.

11. Slominski AT, Kim T-K, Takeda Y, Takeda Y, Janjetovic Z, Brozyna AA, Skobowiat C, Wang J,

Postlethwaite A, Li W, Tuckey RC, Jetten AM. ROR and ROR are expressed in human skin and serve

as receptors for endogenously produced noncalcemic 20-hydroxy-and 20,23-dihydroxyvitamin D. FASEB

J. 2014 July;28(7):2775-89. doi: 10.1096/fj.13-242040. [Epub March 25, 2014] PMID: 24668754.

12. Tang B, Kim S, Hammond S, Cullins DL, Brand DD, Rosloniec EF, Stuart JM, Postlethwaite A, Kang

AH, Myers LK. Characterization of T cell phenotype and function in a double transgenic (collagen-

specific TCR/HLA-DR1) humanized model of arthritis. Arthritis Res Ther. 2014 Jan 10;16(1):R7. doi:

10.1186/ar4433. PMID: 24405551.

13. Slominski AT, Kim TK, Li W, Yi AK, Postlethwaite A, Tuckey RC. The role of CYP11A1 in the

production of vitamin D metabolites and their role in the regulation of epidermal functions. J Steroid

Biochem Mol Biol. 2014 Oct 28;144PA:28-39. doi: 10.1016/j.jsbmb.2013.10.012. PMID: 24176765.

PMCID: PMC4002668.

14. Slominski A, Janjetovic Z, Tuckey RC, Nguyen MN, Bhattacharya KG, Wang J, Li W, Jiao Y, Gu W,

Brown M, Postlethwaite AE. 20S-hydroxyvitamin D3, noncalcemic product of CYP11A1 action on

vitamin D3, exhibits potent antifibrogenic activity in vivo. J Clin Endocrinol Metab. 2013 Feb;98(2):E298-

303. doi: 10.1210/jc.2012-3074. Epub 2013 Jan 7. PMID: 23295467.

http://www.scopus.com/

http://www.ncbi.nlm.nih.gov/pubmed/24176765


Postlethwaite CV

10/18/2016

of 26

15. Slominski AT, Kim TK, Shehabi HZ, Semak I, Tang EK, Nguyen MN, Benson HA, Korik E, Janjetovic

Z, Chen J, Yates CR, Postlethwaite A, Li W, Tuckey RC. In vivo evidence for a novel pathway of vitamin

D₃ metabolism initiated by P450scc and modified by CYP27B1. FASEB J. 2012 Sep;26(9):3901-15. doi:

10.1096/fj.12-208975. Epub 2012 Jun 8. PMID: 22683847.

16. Wang J, Slominski A, Tuckey RC, Janjetovic Z, Kulkarni A, Chen J, Postlethwaite AE, Miller D, Li W.

20-hydroxyvitamin D3 inhibits proliferation of cancer cells with high efficacy while being non-toxic.

Anticancer Res. 2012 Mar;32(3):739-46. PMID: 22399586.

17. Brown M, Postlethwaite AE, Myers LK, Hasty KA. Supernatants from culture of type I collagen-

stimulated PBMC from patients with cutaneous systemic sclerosis versus localized scleroderma

demonstrate suppression of MMP-1 by fibroblasts. Clin Rheumatol. 2012;31(6):973-81. PMID:

22367096.

18. Nashid M, Khanna PP, Furst DE, Clements PJ, Maranian P, Seibold J, Postlethwaite AE, Louie JS, Mayes

MD, Agrawal H, Khanna D: Investigators of the D-penicillamine, human recombinant relaxin and oral

bovine type I collagen clinical trials. Gender and ethnicity differences in patients with diffuse systemic

sclerosis--analysis from three large randomized clinical trials. Rheumatology (Oxford). 2011

Feb;50(2):335-42. Epub 2010 Oct 1. PMID: 20889574.

19. Slominski AT, Li W, Bhattacharya SK, Smith RA, Johnson PL, Chen J, Nelson KE, Tuckey RC, Miller

D, Jiao Y, Gu W, Postlethwaite AE. Vitamin D analogs 17,20S(OH)2pD and 17,20R(OH)2pD are

noncalcemic and exhibit antifibrotic activity. J Invest Dermatol. 2011 May;131(5):1167-doi:

10.1038/jid.2010.425. [Epub 2011 Jan 13] PMID: 21228816.

20. Yin Z, Carbone LD, Gotoh M, Postlethwaite A, Bolen AL, Tigyi GJ, Murakami-Murofushi K, Watsky

MA. Lysophosphatidic acid-activated Cl- current activity in human systemic sclerosis skin fibroblasts.

Rheumatology (Oxford). 2010 Dec;49(12):2290-7. Epub 2010 Sep 7. PMID: 20823096. PMCID:

PMC2981513.

21. Atamas SP, Luzina IG, Ingels J, Choi J, Wong WK, Furst DE, Clements PJ, Investigators of the Oral

Collagen Trial in Scleroderma, Postlethwaite AE. Stimulation with type I collagen induces changes in

gene expression in peripheral blood mononuclear cells from patients with diffuse cutaneous systemic

sclerosis (scleroderma). Clin Exp Immunol. 2010 Sep;16(3):426-35. doi: 10.111/j.1365-

2249.2010.04189.x. May 31. [Epub ahead of print] PMID: 20529088.

22. Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, Khanna PP, Khanna D;

Investigators of the D-Penicillamine, Human Recombinant Relaxin, and Oral Bovine Type I Collagen

Clinical Trials. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials:

analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum. 2009

Aug;60(8):2490-8. doi 10.1002/art.24681. PMID: 19644851. PMCID: PMC2725229.

23. Kaldas M, Khanna PP, Furst DE, Clements PJ, Kee Wong W, Seibold JR, Postlethwaite AE, Khanna D;

investigators of the human recombinant relaxin and oral bovine collagen clinical trials. Sensitivity to

change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body

sites in two large randomized controlled trials. Rheumatology (Oxford). 2009 Sep;48(9):1143-6. Epub

2009 Jul 14. PMID: 19605370. PMCID: PMC2734267.

24. Tokumura A, Carbone LD, Yoshioka Y, Morishige J, Kikuchi M, Postlethwaite A, Watsky MA. Elevated

serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis.

Int J Med Sci. 2009 Jun 5;6(4):168-76. PMID: 19521548. PMCID: PMC2695151.

25. Xiong Q, Jiao Y, Hasty KA, Stuart JM, Postlethwaite A, Kang AH, Gu W. Genetic and molecular basis

of quantitative trait loci of arthritis in rat: genes and polymorphisms. J Immunol. 2008 Jul 15;181(2):859-

64. PMID: 18606636.

26. Postlethwaite AE, Wong WK, Clements P, Chatterjee S, Fessler BJ, Kang AH, Korn J, Mayes M, Merkel

PA, Molitor JA, Moreland L, Rothfield N, Simms RW, Smith EA, Spiera R, Steen V, Warrington K,

White B, Wigley F, Furst DE. A multicenter, randomized, double-blind, placebo-controlled trial of oral

type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does



Postlethwaite CV

10/18/2016

of 26

not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum. 2008

Jun;58(6):1810-22. doi: 10.1002/art.23501. PMID: 18512816.

27. Chiang TM, Postlethwaite AE. Alteration in protein kinase B (AKT) activity in platelets from patients

with systemic sclerosis. Thromb Res. 2008;122(4):501-6. Epub 2008 Mar 19. PMID: 18355897.

28. Khanna D, Clements PJ, Postlethwaite AE, Furst DE. Does incorporation of aids and devices make a

difference in the score of the health assessment questionnaire-disability index? Analysis from a

scleroderma clinical trial. J Rheumatol. 2008 Mar;35(3):466-8. Epub 2007 Dec 15. PMID: 18085737.

29. Postlethwaite AE, Chiang TM. Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin

Rheumatol. Review. 2007 Nov;19(6):574.9. PMID: 17917538.

30. Chiang TM, Postlethwaite AE. A cell model system to study regulation of phosphatidylinositol 3-kinase

and protein kinase B activity by cytokines/growth factors produced by type I collagen stimulated immune

cells from patients with systemic sclerosis. Biochem Biophys Acta. 2007 Aug;1770(8):1181-6. Epub 2007

Apr. PMID: 17524560. PMCID: PMC2083118.

31. Khanna D, Furst DE, Wong WK, Tsevat J, Clements PJ, Park GS, Postlethwaite AE, Ahmed M, Ginsburg

S, Hays RD, Scleroderma Collagen Type 1 Study Group. Reliability, validity, and minimally important

differences of the SF-6D in systemic sclerosis. Qual Life Res. 2007 Aug;16(6):1083-92. Epub 2007 Apr

3. PMID: 17404896.

32. Kanangat S, Postlethwaite A, Cholera S, Williams L, Schaberg D. Modulation of virulence gene

expression in Staphylococcus aureus by interleukin-1beta: novel implications in bacterial pathogenesis.

Microbes Infect. 2007 Mar;9(3):408-15. PMID: 17307379.

33. Kanangat S, Postlethwaite A, Hasty K, Kang A, Smeltzer M, Appling W, Schaberg Induction of multiple

matrix metalloproteinases in human dermal and synovial fibroblasts by Staphylococcus aureus:

implications in the pathogenesis of septic arthritis and other soft tissue infections. Arthritis Res Ther.

2006;8(6):R176. PMID: 17129374. PMCID: PMC1794521.

34. Carbone LD, Warrington KJ, Barrow KD, Pugazhenthi M, Watsky MA, Somes G, Ingels J, Postlethwaite

AE. Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell

cytokine profiles. Clin Exp Immunol. 2006 Dec;146(3):371-80. PMID: 17100755. PMCID:

PMC1810407.

35. Pugazhenthi M, Cooper D, Ratnakant BS, Postlethwaite A, Carbone L. Hypercapnic respiratory failure

in systemic sclerosis. J Clin Rheumatol. 2003 Feb;9(1):43-6. PMID: 17041422.

36. Warrington KJ, Nair U, Carbone LD, Kang AH, Postlethwaite AE. Characterization of the immune

response to type I collagen in scleroderma. Arthritis Res Ther. 2006;8(4):R136. PMID: 16879746.

PMCID: PMC1779396.

37. Kanangat S, Postlethwaite AE, Higgins GC, Hasty KA. Novel functions of intracellular IL-1ra in human

dermal fibroblasts: implications in the pathogenesis of fibrosis. J Invest Dermatol. 2006 Apr;126(4):756-

65. PMID: 16456536.

38. Chiang TM, Takayama H, Postlethwaite AE. Increase in platelet non-integrin type I collagen receptor in

patients with systemic sclerosis. Thromb Res. 2006;117(3):299-306. PMID: 16378833.

39. Chiang TM, Postlethwaite AE. Increase in phosphotidylinositide-3 kinase activity by nitrotyrosylation

of lysates of platelets from patients with systemic sclerosis. Biochem Biophys Acta. 2006 Jan;1760(1):32-

7. Epub 2005 Sep 20. PMID: 16271833.

40. Wang B, Ansari R, Sun Y, Postlethwaite AE, Weber KT, Kiani MF. The scar neovasculature after

myocardial infarction in rats. Am J Physiol Heart Circ Physiol. 2005 Jul;289(1):H108-13. Epub 2005 Feb

18. PMID: 15722410.

41. Takagi K, Takagi M, Kanangat S, Warrington KJ, Shigemitsu H, Postlethwaite AE. Modulation of TNF-

alpha gene expression by IFN-gamma and pamidronate in murine macrophages: regulation by STAT1-

dependent pathways. J Immunol. 2005 Feb15;174(4):1801-10. PMID: 15699106.

42. Carbone LD, McKown K, Pugazhenthi M, Barrow KD, Warrington K, Somes G, Postlethwaite AE.

Dosage effects of orally administered bovine type I collagen on immune function in patients with systemic

Postlethwaite CV

10/18/2016

of 26

sclerosis. Arthritis Rheum. 2004 Aug;50(8):2713-5. PMID: 15334493.

43. Ahokas RA, Warrington KJ, Gerling IC, Sun Y, Wodi LA, Herring PA, Lu L, Bhattacharya SK,

Postlethwaite AE, Weber KT. Aldosteronism and peripheral blood mononuclear cell activation: a

neuroendocrine-immune interface. Circ Res. 2003 Nov 14;93(10):e124-35. PMID: 14576195.

44. Gerling IC, Sun Y, Ahokas RA, Wodi LA, Bhattacharya SK, Warrington KJ, Postlethwaite AE, Weber

KT. Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype.

Am J Physiol Heart Circ Physiol. 2003 Aug;285(2):H813-21. PMID: 12860567.

45. Myers LK, Higgins GC, Finkel TH, Reed AM, Thompson JW, Walton RC, Hendrickson J, Kerr NC,

Pandya-Lipman RK, Shlopov BV, Stastny P, Postlethwaite AE, Kang AH. Juvenile arthritis and

autoimmunity to type II collagen. Arthritis Rheum. 2001 Aug;44(8):1775-81. PMID: 11508428.

46. Myers LK, Kang AH, Postlethwaite AE, Rosloniec EF, Morham SG, Shlopov BV, Goorha S, Ballou LR.

The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis

Rheum. 2000 Dec;43(12):2687-93. PMID: 11145026.

47. Kanangat S, Bronze MS, Meduri GU, Postlethwaite A, Stentz F, Tolley E, Schaberg D. Enhanced

extracellular growth of Staphylococcus aureus in the presence of selected linear peptide fragments of

human interleukin (IL)-1beta and IL-1 receptor antagonist. J Infect Dis. 2001 Jan 1;183(1):65-9. Epub

2000 Nov. PMID: 11076706.

48. McKown KM, Carbone LD, Bustillo J, Seyer JM, Kang AH, Postlethwaite AE. Induction of immune

tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine

type I collagen. Arthritis Rheum. 2000 May;43(5):1054-61. PMID: 10817559. doi: 10.1002/1529-

0131(200005)43:5<1054::AID-ANR14L3.0.CO;2-W.

49. Higgins GC, Wu Y, Postlethwaite AE. Intracellular IL-1 receptor antagonist is elevated in human dermal

fibroblasts that overexpress intracellular precursor IL-1 alpha. J Immunol. 1999 Oct 1;163(7):3969-75.

PMID: 10490999.

50. Tan FK, Arnett FC, Antohi S, Saito S, Mirarchi A, Spiera H, Sasaki T, Shoichi O, Takeuchi K, Pandey

JP, Silver RM, LeRoy C, Postlethwaite AE, Bona CA. Autoantibodies to the extracellular matrix

microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases.

J Immunol. 1999 Jul 15;163(2):1066-72. PMID: 10395706.

51. McKown KM, Carbone LD, Kaplan SB, Aelion JA, Lohr KM, Cremer MA, Bustillo J, Gonzalez M,

Kaeley G, Steere EL, Somes GW, Myers LK, Seyer JM, Kang AH, Postlethwaite AE. Lack of efficacy

of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. Arthritis Rheum. 1999

Jun;42(6):1204-8. PMID: 10366113.

52. Meduri GU, Tolley EA, Chinn A, Stentz F, Postlethwaite A. Procollagen types I and III aminoterminal

propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone

treatment. Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 1):1432-41. PMID: 9817690. Erratum in: Am

J Respir Crit 2013 Dec 15;188(12):1477.

53. Solomon SS, Mishra SK, Cwik C, Rajanna B, Postlethwaite AE. Pioglitazone and metformin reverse

insulin resistance induced by tumor necrosis factor-alpha in liver cells. Horm Metab Res. 1997

Aug;29(8):379-82. PMID: 9288574.

54. Solomon SS, Mishra SK, Palazzolo MR, Postlethwaite AE, Seyer JM. Identification of specific sites in

the TNF-alpha molecule promoting insulin resistance in H-411E cells. J Lab Clin Med. 1997

Aug;130(2):139-46. PMID: 9280141.

55. Armendariz-Borunda J, Endres RO, Ballou LR, Postlethwaite AE. Transforming growth factor-beta

inhibits interferon-gamma-induced HLA-DR expression by cultured human fibroblasts. Int J Biochem

Cell Biol. 1996 Oct;28(10):1107-16. PMID: 8930134.

56. Higgins GC, Postlethwaite AE. Synovial fluid from patients with rheumatoid arthritis contains a unique

inhibitor of interleukin 1 alpha. J Rheumatol. 1996 Jun;23(6):965-73. PMID: 8782124.

57. White, B, Bauer EA, Goldsmith LA, Hochberg MC, Katz LM, Korn JH, Lachenbruch PA, LeRoy EC,

Mitrane MP, Paulus HE, Postlethwaite AE, Steen VD. Guidelines for clinical trials in systemic sclerosis

Postlethwaite CV

10/18/2016

of 26

(scleroderma). 1. Disease-modifying interventions. The American College of Rheumatology Committee

on Design and Outcomes in Clinical Trials in Systemic Sclerosis. Arthritis Rheum. 1995 Mar;38(3):351-

360. PMID: 7880189.

58. Meduri GU, Headley S, Tolley E, Shelby M, Stentz F, Postlethwaite A. Plasma and BAL cytokine

response to corticosteroid rescue treatment in late ARDS. Chest. 1995 Nov;108(5):1315-25. PMID:

7587435.

59. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A. Inflammatory cytokines in the

BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest. 1995

Nov;108(5):1303-14. PMID: 7587434.

60. Moreland LW, Pratt PW, Mayes MD, Postlethwaite A, Weisman MH, Schnitzer T, Lightfoot R,

Calabrese L, Zelinger DJ, Woody JN, Koopman WJ. Double-blind, placebo-controlled multicenter trial

using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving

concomitant methotrexate. Arthritis Rheum. 1995 Nov;38(11):1581-8. doi: 10.1002/arts/1780381109.

PMID: 7488278.

61. Ballou LR, Postlethwaite AE, Kang AH. The effect of misoprostol on arachidonic acid mobilization,

prostaglandin E(2), production, and IL-1beta signaling. Am J Ther. 1995 Sep;2(9):630-6. PMID:

11854839.

62. Postlethwaite AE, Seyer JM. Identification of a chemotactic epitope in human transforming growth

factor-beta 1 spanning amino acid residues 368-374. J Cell Physiol. 1995 Sep;164(3):587-92. PMID:

7650066.

63. Postlethwaite AE, Raghow R, Stricklin G, Ballou L, Sampath TK. Osteogenic protein-1, a bone

morphogenic protein member of the TGF-beta superfamily, shares chemotactic but not fibrogenic

properties with TGF-beta. J Cell Physiol. 1994 Dec;161(3):562-70. PMID: 7962137.

64. Higgins GC, Foster JL, Postlethwaite AE. Interleukin 1 beta propeptide is detected intracellularly and

extracellularly when human monocytes are stimulated with LPS in vitro. J Exp Med. 1994 Aug

1;180(2):607-14. PMID: 8046336. PMCID: PMC2191596.

65. Hong L, Imeri L, Opp MR, Postlethwaite AE, Seyer JM, Krueger JM. Intercellular adhesion molecule-1

expression induced by interleukin (IL)-1 beta or an IL-1 beta fragment is blocked by an IL-1 receptor

antagonist and a soluble IL-1 receptor. J Neuroimmunol. 1993 May;44(2):163-70. PMID: 8099361.

66. Postlethwaite AE, Holness MA, Katai H, Raghow R. Human fibroblasts synthesize elevated levels of

extracellular matrix proteins in response to interleukin 4. J Clin Invest. 1992 Oct;90(4):1479-85. PMID:

1401080. PMID: 1401080. PMCID: PMC443194.

67. Kapás L, Hong L, Cady AB, Opp MR, Postlethwaite AE, Seyer JM, Krueger JM. Somnogenic,

pyrogenic, and anorectic activities of tumor necrosis factor-alpha and TNF-alpha fragments. Am J Physiol.

1992 Sep;263(3 Pt 2):R708-15. PMID: 1357984.

68. Opp MR, Postlethwaite AE, Seyer JM, Krueger JM. Interleukin 1 receptor antagonist blocks somnogenic

and pyrogenic responses to an interleukin 1 fragment. Proc Natl Acad Sci U S A. 1992 May 1;89(9):3726-

30. PMID: 1533282. PMCID: PMC525563.

69. Armendariz-Borunda J, Seyer JM, Postlethwaite AE, Kang AH. Kupffer cells from carbon tetrachloride-

injured rat livers produce chemotactic factors for fibroblasts and monocytes: the role of tumor necrosis

factor-alpha. Hepatology. 1991 Nov;14(5):895-900. PMID: 1937392.

70. Postlethwaite AE, Seyer JM. Fibroblast chemotaxis induction by human recombinant interleukin-4.

Identification by synthetic peptide analysis of two chemotactic domains residing in amino acid sequences

70-88 and 89-122. J Clin Invest. 1991 Jun;87(6):2147-52. PMID: 2040697. PMCID:PMC296973.

71. Fava RA, Olsen NJ, Postlethwaite AE, Broadley KN, Davidson JM, Nanney LB, Lucas C, Townes AS.

Transforming growth factor beta 1 (TGF-beta 1) induced neutrophil recruitment to synovial tissues:

implications for TGF-beta-driven synovial inflammation and hyperplasia. J Exp Med. 1991 May

1;173(5):1121-32. PMID: 2022923. PMCID: PMC2118851.

72. Prakash S, Postlethwaite AE, Wyler DJ. Alterations in influence of granuloma-derived cytokines on

Postlethwaite CV

10/18/2016

of 26

fibrogenesis in the course of murine Schistosoma mansoni infection. Hepatology. 1991 May;13(5):970-6.

PMID: 1903125.

73. Ballou LR, Barker SC, Postlethwaite AE, Kang AH. Interleukin 1 stimulates phosphatidylinositol kinase

activity in human fibroblasts. J Clin Invest. 1991 Jan;87(1):299-304. PMID: 1845871. PMCID:

PMC295050.

74. Ballou LR, Barker SC, Postlethwaite AE, Kang AH. Sphingosine potentiates IL-1-mediated

prostaglandin E2 production in human fibroblasts. J Immunol. 1990 Dec 15;145(12):4245-51. PMID:

2124239.

75. Postlethwaite AE, Seyer JM. Stimulation of fibroblast chemotaxis by human recombinant tumor necrosis

factor alpha (TNF-alpha) and a synthetic TNF-alpha 31-68 peptide. J Exp Med. 1990 Dec 1;172(6):1749-

56. PMID: 2258704. PMCID: PMC2188741.

76. Obal F Jr, Opp M, Cady AB, Johannsen L, Postlethwaite AE, Poppleton HM, Seyer JM, Krueger JM.

Interleukin 1 alpha and an interleukin 1 beta fragment are somnogenic. Am J Physiol. 1990 Sep;259(3 Pt

2):R439-46. PMID: 2396703.

77. Cush JJ, Lipsky PE, Postlethwaite AE, Schrohenloher RE, Saway A, Koopman WJ. Correlation of

serologic indicators of inflammation with effectiveness of nonsteroidal anti-inflammatory drug therapy in

rheumatoid arthritis. Arthritis Rheum. 1990 Jan;33(1):19-28. PMID: 2302265.

78. Prakash S, Postlethwaite AE, Stricklin GP, Wyler DJ. Fibroblast stimulation in schistosomiasis. IX.

Schistosomal egg granulomas from congenitally athymic mice are deficient in production of fibrogenic

factors. J Immunol. 1990 Jan 1;144(1):317-22. PMID: 2153167.

79. Drake S, Massie JD, Postlethwaite AE, Palmieri GM. Pamidronate sodium and calcitonin-resistant

Paget's disease. Immediate response in a patient. Arch Intern Med. 1989 Feb;149(2):401-3. PMID:

2783843.

80. Postlethwaite AE, Smith GN Jr, Lachman LB, Endres RO, Poppleton HM, Hasty KA, Seyer JM, Kang

AH. Stimulation of glycosaminoglycan synthesis in cultured human dermal fibroblasts by interleukin 1.

Induction of hyaluronic acid synthesis by natural and recombinant interleukin 1s and synthetic interleukin

1 beta peptide 163-171. J Clin Invest. 1989 Feb;83(2):629-36. PMID: 2783590. PMCID: PMC303724.

81. Bever CT Jr, Snyder DS, Endres RO, Morgan KD, Postlethwaite A, Whitaker JN. Activation of astrocytic

lysosomal proteinases by factors released by mononuclear leukocytes. Neurochem Res. 1989

Jan;14(1):37-41. PMID: 2710277.

82. Keski-Oja J, Raghow R, Sawdey M, Loskutoff DJ, Postlethwaite AE, Kang AH, Moses HL. Regulation

of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming

growth factor-beta. Divergent responses in lung fibroblasts and carcinoma cells. J Biol Chem. 1988 Mar

5;263(7):3111-5. PMID: 3125175.

83. Postlethwaite AE, Raghow R, Stricklin GP, Poppleton H, Seyer JM, Kang AH. Modulation of fibroblast

functions by interleukin 1: increased steady-state accumulation of type I procollagen messenger RNAs

and stimulation of other functions but not chemotaxis by human recombinant interleukin 1 alpha and beta.

J Cell Biol. 1988 Feb;106(2):311-8. PMID: 2828381. PMCID: PMC2114989.

84. Postlethwaite AE, Kang AH. Advantages and limitations of in vitro models of wound healing and tissue

repair. Prog Clin Biol Res. 1988;266:237-42. PMID: 3380848.

85. Postlethwaite AE, Kang AH. Fibroblast chemoattractants. Methods Enzymol. 1988;163:694-707. PMID:

3237093.

86. Keski-Oja J, Postlethwaite AE, Moses HL. Transforming growth factors in the regulation of malignant

cell growth and invasion. Review. Cancer Invest. 1988;6(6):705-24. PMID: 3072995. Online ISSN: 1532-

4192. URL: http://www.tandfonline.com/doi/abs/10.3109/07357908809078038

87. Wyler DJ, Ehrlich HP, Postlethwaite AE, Raghow R, Murphy MM. Fibroblast stimulation in

schistosomiasis. VII. Egg granulomas secrete factors that stimulate collagen and fibronectin synthesis.

J Immunol. 1987 Mar 1;138(5):1581-6. PMID: 3100642.

88. Ochs ME, Postlethwaite AE, Kang AH. Identification of a protein in sera of normal humans that inhibits

http://www.tandfonline.com/doi/abs/10.3109/07357908809078038

Postlethwaite CV

10/18/2016

of 26

fibroblast chemotactic and random migration in vitro. J Invest Dermatol. 1987 Feb;88(2):183-90. PMID:

3805756.

89. Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH. Stimulation of the chemotactic migration of human

fibroblasts by transforming growth factor beta. J Exp Med. 1987 Jan 1;165(1):251-6. PMID: 3491869.

PMCID: PMC2188256.

90. Hernandez AD, Hibbs MS, Postlethwaite AE. Establishment of basal cell carcinoma in culture: evidence

for a basal cell carcinoma-derived factor(s) which stimulates fibroblasts to proliferate and release

collagenase. J Invest Dermatol. 1985 Nov;85(5):470-5. PMID: 2414370.

91. Postlethwaite AE, Lachman LB, Kang AH. Induction of fibroblast proliferation by interleukin-1 derived

from human monocytic leukemia cells. Arthritis Rheum. 1984 Sep;27(9):995-1001. PMID: 6332633.

92. Kang ES, Postlethwaite A, Schaeffer S, Sawhney B. Endogenous surface phosphorylation reactions and

ectokinase activity in the guinea pig T lymphocyte. Cell Immunol. 1984 Sep;87(2):319-26. PMID:

6331892.

93. Postlethwaite AE, Smith GN, Mainardi CL, Seyer JM, Kang AH. Lymphocyte modulation of fibroblast

function in vitro: stimulation and inhibition of collagen production by different effector molecules. J

Immunol. 1984 May;132(5):2470-7. PMID: 6609200.

94. Floyd RA, Kuo CY, Yoo TJ, Song A, Postlethwaite AE, Mainardi C. Protease inhibition of natural killer

(NK) and antibody-dependent cell-mediated cytotoxicity (ADCC) activities. J Lab Clin Med. 1984

Feb;103(2):215-22. PMID: 6693794.

95. Wyler DJ, Postlethwaite AE. Fibroblast stimulation in schistosomiasis. IV. Isolated egg granulomas

elaborate a fibroblast chemoattractant in vitro. J Immunol. 1983 Mar 1;130(3):1371-5. PMID: 6822739.

96. Postlethwaite AE, Lachman LB, Mainardi CL, Kang AH. Interleukin 1 stimulation of collagenase

production by cultured fibroblasts. J Exp Med. 1983 Feb 1;157(2):801-6. PMID: 6296266. PMCID:

PMC2186943.

97. Postlethwaite AE, Kang AH. Induction of fibroblast proliferation by human mononuclear leukocyte-

derived proteins. Arthritis Rheum. 1983 Jan;26(1):22-7. PMID: 6600611.

98. Hibbs MS, Postlethwaite AE, Mainardi CL, Seyer JM, Kang AH. Alterations in collagen production in

mixed mononuclear leukocyte-fibroblast cultures. J Exp Med. 1983 Jan 1;157(1):47-59. PMID: 6549655.

PMCID: PMC2186892.

99. Postlethwaite AE, Kang AH. Characterization of fibroblast proliferation factors elaborated by antigen-

and mitogen-stimulated guinea pig lymph node cells: differentiation from lymphocyte-derived

chemotactic factor for fibroblasts, lymphocyte mitogenic factor, and interleukin 1. Cell Immunol. 1982

Oct;73(1):169-78. PMID: 6217901.

100. Postlethwaite AE, Jackson BK, Beachey EH, Kang AH. Formation of multinucleated giant cells from

human monocyte precursors. Mediation by a soluble protein from antigen-and mitogen-stimulated

lymphocytes. J Exp Med. 1982 Jan 1;155(1):168-78. PMID: 7054356. PMCID: PMC2186572.

101. Postlethwaite AE, Keski-Oja J, Balian G, Kang AH. Induction of fibroblast chemotaxis by fibronectin.

Localization of the chemotactic region to a 140,000-molecular weight non-gelatin-binding fragment. J

Exp Med. 1981 Feb 1;153(2):494-9. PMID: 7241050. PMCID: PMC2186091.

102. Postlethwaite AE. Isolation and characterization of lymphocyte mitogenic factor released in vivo during

a cell-mediated immune reaction in the guinea pig. J Immunol. 1980 Nov;125(5):1955-8. PMID: 6968767.

103. Stuart JM, Postlethwaite AE, Townes AS, Kang AH. Cell-mediated immunity to collagen and collagen

alpha chains in rheumatoid arthritis and other rheumatic diseases. Am J Med. 1980 Jul;69(1):13-8. PMID:

7386498.

104. Postlethwaite AE, Kang AH. Characterization of guinea pig lymphocyte-derived chemotactic factor for

fibroblasts. J Immunol. 1980 Mar;124(3):1462-6. PMID: 7358987.

105. Postlethwaite AE, Snyderman R, Kang AH. Generation of a fibroblast chemotactic factor in serum by

activation of complement. J Clin Invest. 1979 Nov;64(5):1379-85. PMID: 91624. PMCID: PMC371286.

106. Postlethwaite AE, Kang AH. Latent lymphokines: isolation of guinea pig latent lymphocyte-derived

Postlethwaite CV

10/18/2016

of 26

chemotactic factor for monocytes. Its activation by trypsin and a soluble factor from macrophages. J

Immunol. 1979 Aug;123(2):561-7. PMID: 711857.

107. Chiang TM, Postlethwaite AE, Beachey EH, Seyer JM, Kang AH. Binding of chemotactic collagen-

derived peptides to fibroblasts. The relationship to fibroblast chemotaxis. J Clin Invest. 1978

Nov;62(5):916-22. PMID: 711857. PMCID: PMC371848.

108. Postlethwaite AE, Seyer JM, Kang AH. Chemotactic attraction of human fibroblasts to type I, II, and III

collagens and collagen-derived peptides. Proc Natl Acad Sci U S A. 1978 Feb;75(2):871-5. PMID:

204938. PMCID: PMC411359.

109. Postlethwaite AE, Snyderman R, Kang AH. The chemotactic attraction of human fibroblasts to a

lymphocyte-derived factor. J Exp Med. 1976 Nov 2;144(5):1188-203. PMID: 825607. PMCID:

PMC2190454.

110. Postlethywaite AE, Townes AS, Kang AH. Characterization of macrophage migration inhibitory factor

activity produced in vivo by a cell-mediated immune reaction in the guinea pig. J Immunol. 1976

Nov;117(5 Pt 1):1716-20. PMID: 794416. (PubMed correction for name “Postlethywaite” in process).

111. Postlethwaite AE, Kang AH. Guinea pig lymphocyte-derived macrophage aggregation factor: its

separation from macrophage migration inhibitory factor. J Immunol. 1976 Nov;117(5 Pt 1):1651-5.

PMID: 794415.

112. Stuart JM, Postlethwaite AE, Kang AH. Evidence for cell-mediated immunity to collagen in progressive

systemic sclerosis. J Lab Clin Med. 1976 Oct;88(4):601-7. PMID: 965811.

113. Postlethwaite AE, Kang AH. Collagen-and collagen peptide-induced chemotaxis of human blood

monocytes. J Exp Med. 1976 Jun 1;143(6):1299-307. PMID: 1271012. PMCID: PMC2190221.

114. Stuart JM, Postlethwaite AE, Kang AH. Proceedings: Evidence of cell-mediated immunity to collagen

in patients with progressive systemic sclerosis. Arthritis Rheum. 1975 Sep-Oct;18(5):525-6. Online ISSN:

1529-0131. PMID: 1191358.

115. Postlethwaite AE, Snyderman R. Characterization of chemotactic activity produced in vivo by a cell-

mediated immune reaction in the guinea pig. J Immunol. 1975 Jan;114(1 Pt 2):274-8. PMID: 1117129.

116. Postlethwaite AE, Gutman RA, Kelley WN. Salicylate-mediated increase in urate removal during

hemodialysis: evidence for urate binding to protein in vivo. Metabolism. 1974 Aug;23(8):771-7. PMID:

4854190.

117. Postlethwaite AE, Ramsdell CM, Kelley WN. Uricosuric effect of anticholinergic agent in hyperuricemic

subjects. Arch Intern Med. 1974 Aug;134(2):270-5. PMID: 4843194.

118. Ramsdell CM, Postlethwaite AE, Kelley WN. Uricosuric effect of glyceryl guaiacolate. J Rheumatol.

1974 Mar;1(1):114-6. PMID: 4617771.

119. Postlethwaite AE, Ramsdell CM, Kelley WN. Uricosuric effect of an anticholinergic agent in

hyperuricemic subjects. Adv Exp Med Biol. 1974;41:769-76. PMID: 4832607.

120. Postlethwaite AE, Bartel AG, Kelley WN. Hyperuricemia induced by ethambutol. Adv Exp Med Biol.

1974;41:763-7. PMID: 4832606.

121. Postlethwaite AE, Kelley WN. Studies on the mechanism of ethambutol-induced hyperuricemia. Arthritis

Rheum. 1972 Jul-Aug;15(4):403-9. PMID: 5046470.

122. Postlethwaite AE, Bartel AG, Kelley WN. Hyperuricemia due to ethambutol. N Engl J Med. 1972 Apr

6;286(14):761-2. PMID: 5025779.

123. Postlethwaite AE, Kelley WN. Radiocontrast agents and aspirin. JAMA. 1972 Mar 13;219(11):1479.

PMID: 5066914.

124. Postlethwaite AE, Kelley WN. Uricosuric effect of radiocontrast agents. A study in man of four

commonly used preparations. Ann Intern Med. 1971 Jun;74(6):845-52. PMID: 5580635.

Postlethwaite CV

10/18/2016

of 26

Publications: Chapters in Books, Reviews, and Invited Articles

1. Postlethwaite AE. Vasculitis: A Consideration of Causes and Mediators. In: Ann Rev Allergy., C.A.

Frazier, ed., Flushing, N.Y., Medical Examination Publishing Co., Inc., 1974, pp 336-47.

2. Postlethwaite AE. Vasculitis: A Consideration of Causes and Mediators. In: Ann Rev Allergy., C.A.

Frazier, ed., Flushing, N.Y., Medical Examination Publishing Co., Inc., 1975, pp 176-81.

3. Townes, AS, Postlethwaite AE. Lymphocyte surface markers in human disease. Adv Intern Med.

1977(22):97-119. Review. PMID: 320850.

4. Postlethwaite AE. Cell-Cell Interaction Collagen Biosynthesis and Fibroblast Migration. In: Advances

in Inflammation Research, Vol. 5, Gerald Wiseman, ed., Raven Press, New York, 1983, pp. 27-55.

5. Kang AH, Seyer JM, Postlethwaite AE, Hibbs MS, Mainardi CL. Collagen polymorphism in lung

fibrosis. J UOEH (JAPAN) 1982;4(Suppl):95-107.

6. Postlethwaite AE, Kang AH. Pathogenesis of progressive systemic sclerosis. J Lab Clin Med. 1984 Apr;

103(4):506-10. PMID: 6607964.

7. Postlethwaite AE, Stuart JM, Kang AH. The Cell-Mediated Immune System in Progressive Systemic

Sclerosis. In: Systemic Sclerosis: Current Topics in Rheumatology. Carol Black and Allen Myers, eds.

Gower Medical Publishing, Ltd., New York, 1985. pp 319-25.

8. Postlethwaite AE, Kang AH. Modulation of Fibroblast Function by Soluble Mediators from Mononuclear

Leukocytes. In: Systemic Sclerosis: Current Topics in Rheumatology, Carol Black and Allen Myers, eds.

Gower Medical Publishing, Ltd., New York, 1985. pp 362-69.

9. Postlethwaite AE, Kang AH. Fibroblast Chemoattractants. In: Methods in Enzymology: Chemotaxis and

Inflammation. Giovanni Di Sabato, ed., Academic Press, Inc., Orlando, FL, 1986. pp. 695-707.

10. Raghow R, Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH. Transforming growth factor-beta

increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally

in cultured human dermal fibroblasts. J Clin Invest. 1987 Apr;79(4):1285-8. doi:

10.3109/07357908809078038. Review. PMID: 3470308. PMCID: PMC424335.

11. Postlethwaite AE, Kang AH. Cellular Immunity in Systemic Sclerosis. In: Systemic Sclerosis

Scleroderma. Malcolm Jayson and Carol Black, eds., John Wiley and Sons Limited, New York, NY, 1988,

pp 61-73.

12. Postlethwaite AE, Kang AH. Fibroblasts. In: Inflammation: Basic Principles and Clinical Correlation.

John I. Gallin, Ira M. Goldstein and Ralph Snyderman, eds., Raven Press, New York, NY, 1988, pp 577-

97.

13. Postlethwaite AE. Chronic Inflammation. In: Textbook of Internal Medicine. Eds. W.M. Kelley and E.V.

Harris, Jr. J.B. Lippincott Co., Philadelphia, PA. 1989. pp 965-8.

14. Wyler DJ, Prakash S, Postlethwaite AE. Fibrosis as a Complication of Granulomatous Inflammation:

Lessons Learned from Schistosomiasis. In: Basic Mechanisms of Granulomatous Inflammation. T.

Yoshida and M. Torisu, ed., Elsevier Science Publishers B.V., New York, NY 1989. pp. 241-61.

15. Postlethwaite AE, Kang AH. Advantages and Limitations of In Vitro Models of Wound Healing and

Tissue Repair. In: Growth Factors and Other Aspects of Wound Healing: Biological and Clinical

Implications. Adrian Barbal, Eli Pines, Michael Caldwell and Thomas K. Hunt, eds. Alan R. Liss, Inc.,

New York, 1988. pp. 237-42.

16. Postlethwaite AE. Early immune events in scleroderma. Rheum Dis Clin North Am. 1990 Feb;16(1):125-

39, 1990. Review. PMID: 2406803.

17. Postlethwaite AE. Failed Healing Responses in Connective Tissue and a Comparison of Medical

Conditions. In: Sports Induced Inflammation. Churchill Livingstone, Inc. New York, NY 1990. pp 597-

607.

18. Higgins GC, Postlethwaite AE. Interleukin-1 Inhibitors and Their Significance in Rheumatoid Arthritis.

Ch 7. In: Kresina TF (ed), Monoclonal Antibodies, Cytokines, and Arthritis. Marcel Dekker, Inc., New

York, NY, 1991;133-72.

19. Pisetsky DS, Haynes BF, Lipsky PE, Kang AH, Postlethwaite AE. The specialized centers of research in

Postlethwaite CV

10/18/2016

of 26

rheumatoid arthritis: Recent progress and prospects for future advances. Hum Immunol. 1991

Jun;31(2):148-51. PMID: 2066274.

20. Postlethwaite AE, Kang AH. Fibroblasts and Matrix Proteins. In: Inflammation: Basic Principles and

Clinical Correlation. John I. Gallin, Ira M. Goldstein and Ralph Snyderman, eds., Raven Press, New York,

NY, 1992, pp 747-73.

21. Postlethwaite AE. Connective tissue metabolism including cytokines in scleroderma. Curr Opin

Rheumatol 1993;5:766-72. Review. PMID: 8117540.

22. Postlethwaite AE. Dermal Fibroblast Function. In: Dermal Immune System. B.J. Nickoloff, ed., CRC

Press, Boca Raton, FL. 1993. pp. 163-4.


Rheumatol. 1994;6:616-20. Review. PMID: 7865383.

24. Postlethwaite AE. Role of T cells and cytokines in effecting fibrosis. Intern. Rev. Immunol. 1995;12(2-

4):247-58. Review. PMID: 7650423.


Rheumatol. 1995 Nov;7(6):535-40. Review. PMID: 8579975.

26. Postlethwaite AE. Bidirectional interactions between T cells and the extracellular matrix. Transplant

Immunol. 1997;5(4):289-91. Review. PMID: 9504.

27. Postlethwaite AE. Fibroblasts and Matrix Proteins. In: Inflammation: Basic Principles and Clinical

Correlates. John Gallin and Ralph Snyderman, eds. Lippincott-Raven, Publishers, Philadelphia, PA., pp-

227-57, 1999.

28. Postlethwaite AE. Can we induce tolerance in rheumatoid arthritis? Curr Rheumatol Rheum Reports.

2001;3(1):64-9. Review. PMID: 11177772.

29. Sun Y, Kiani MF, Postlethwaite AE, Weber KT. Infarct scar as living tissue. Basic Res Cardiol. 2002

Sep;97(5):343-7. Review. PMID: 12200633.

30. Weber KT, Sun Y, Wodi LA, Munir A, Jahangir E, Ahokas RA, Gerling IC, Postlethwaite AE,

Warrington KJ. Toward a broader understanding of aldosterone in congestive heart failure. J Renin

Angiotensin Aldosterone Syst. 2003 Sep;4(3):155-63. Review. PMID: 14608519.

31. Weber KT, Gerling IC, Kiani MF, Guntaka RV, Sun Y, Ahokas RA, Postlethwaite AE, Warrington KJ.

Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers

and potential drug targets. Curr Drug Targets. 2003 Aug;4(6):505-16. Review. PMID: 12866665.

32. Postlethwaite AE, Shigemitsu H, Kanangat S. Cellular origins of fibroblasts: possible implications for

organ fibrosis in systemic sclerosis. Curr Opin Rheumatol. 2004 Nov;16(6):733-8. Review. PMID:

15577612.

33. Postlethwaite AE, Chiang TM. Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin

Rheumatol. 2007 Nov;19(6):574-9. Review. PMID: 17917538.

34. Postlethwaite AE, Harris LJ, Raza SH, Kodura S, Akhigbe T. Pharmacotherapy of systemic sclerosis.

Review. Expert Opin Pharmacother. 2010 Apr;11(5):789-809. PMCID: PMC2837533.

35. Watsky MA, Weber KT, Sun Y, Postlethwaite A. New insights into the mechanism of fibroblast to

myofibroblast transformation and associated pathologies. Int Rev Cell Mol Biol. 2010;282:165-92 {Epub

2010 Jun 18}. Review. PMID: 20630469.

36. Pattanaik D, Postlethwaite AE. A role for lysophosphatidic acid and sphingosine 1-phosphate in the

pathogenesis of systemic sclerosis. Discov Med. 2010 Aug;10(51):161-7. Review. PMID: 20807477.

37. Wong WK, Boscardin WJ, Postlethwaite AE, Furst DE. Handling missing data issues in clinical trials

for rheumatic diseases. Contemp Clin Trials. 2011 Jan;32(1):1-9. Epub 2010 Sep 16. Review. PMID:

20840873.

38. Pattanaik D, Brown M, Postlethwaite AE. Vascular involvement in systemic sclerosis (scleroderma).

J Inflamm Res. 2011 Apr;4(1):105-25. Epub 2011 Jul 26. Review. PMID: 22096374.

39. Cao Y, Jiao Y, Wang L, Huang Y, Postlethwaite A, Stuart J, Kang A, Williams RW, Gu W. Anakinra as

an interleukin 1 receptor antagonist, complicated genetics and molecular impacts-from the point of view

Postlethwaite CV

10/18/2016

of 26

of mouse genomics. Int Immunopharmacol. 2012 May;13(1):28-36. Review. PMID: 22425556.

40. Wei W, Jiao Y, Postlethwaite A, Stuart JM, Wang Y, Sun D, Gu W. Dual-specificity phosphatases 2:

surprising positive effect at the molecular level and a potential biomarker of diseases. Genes Immun. 2013

Jan;14(1):1-6. doi: 10.1038/gene.2012.54. Epub 2012 Nov 29. Review. PMID: 23190643

41. Slominski A, Kim TK, Zmijewski MA, Janjetovic Z, Li W, Chen J, Kusniatsova El, Semak I,

Postlethwaite A, Miller DD, Zjawiony JK, Tuckey RC. Novel vitamin D photoproducts and their

precursors in the skin. Dermatoendocrinol. 2013 Jan 1;5(1):7-19. Review. PMID: 24494038.

42. Slominski A, Zbytek B, Nikolakis G, Manna PR, Skobowiat C, Zmijewski M, Li W, Janjetovic Z,

Postlethwaite A, Zouboulis CC, Tuckey RC. Steroidogenesis in the skin: implications for local immune

functions. J Steroid Biochem Mol Biol. 2013 Sep;137:107-23. doi: 10.1016/j.jsbmb.2013.02.006. Epub

2013 Feb 19. Review. PMID: 23435015.

43. Marion TN, Postlethwaite AE. Chance, genetics, and the heterogeneity of disease and pathogenesis in

systemic lupus erythematosus. Semin Immunopath: Mechanisms of Tissue Injury in Autoimmune

Diseases. Sept 2014;36(5):495-517. doi: 10.1007/s00281-014-0440-x. [D. Eilat, ed. Springer, 2014 Aug

8, (Epub ahead of print)]. Review. PMID: 25102991.

44. Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE. Pathogenesis of Systemic Sclerosis.

Research Topic on “Vascular inflammation in systemic autoimmunity”. Hosts: Ramirez GA, Weyand C,

Vaglio A, Manfredi AA. Front Immunol. 2015 Jun 8;6:272. doi: 10.3389/fimmu.2015.00272. eCollection

2015. Review. PMID: 26106387. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459100/





http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459100/

Postlethwaite CV

10/18/2016

of 26

Abstracts (oldest to most recent)

*1. Postlethwaite AE, Kelley WN. The Uricosuric Effect of Iopanoic Acid (Telepaque) In Man. Arthritis

Rheum. 14:181, Jan-Feb 1971.

*2. Postlethwaite AE, Bartel AG, Kelley WN. Ethambutol Induced Hyperuricemia. Arthritis Rheum. 15:122,

Jan-Feb 1972.

*3. Postlethwaite AE, Snyderman R. Mononuclear Leukocyte (MNL) Chemotactic (CTX) Activity in Vivo

in Delayed Hypersensitivity (DH). Fed Proc. 32:988, Mar 1973.

*4. Postlethwaite AE, Ramsdell CM, Kelley WN. Uricosuric Effect of an Anticholinergic Agent in

Hyperuricemic Subjects. Arthritis Rheum. 16:127, Jan-Feb 1973.

*5. Postlethwaite AE, Gutman RA, Kelley WN. Salicylate Mediated Increase in Urate Removal during

Hemodialysis: Evidence for Urate Binding In Vivo. Clin Res. 21:68, January 1973.

*6. Postlethwaite AE, Kang AH. Chemotactic Properties of Collagen. Clin Res. 22:644a, Oct 1974.

*7. Postlethwaite AE, Kang AH. Chemotactic Attraction of Human Fibroblasts to Native Collagen and

Collagen Peptides. Arthritis Rheum. 18:420-421, Jul-Aug 1975.

*8. Stuart JM, Postlethwaite AE, Kang AH. Evidence of Cell-mediated Immunity to Collagen in Patients

with Progressive Systemic Sclerosis. Arthritis Rheum. 18:525, Sep-Oct 1975.

*9. Postlethwaite AE, Snyderman R, Kang AH. Lymphocyte-derived Chemotactic Factor for Fibroblasts: A

New Chemotactic Lymphokine. Clin Res. 23:530a, Nov 1975.

*10. Postlethwaite AE, Kang AH. Kinetic Studies on Migration Inhibitory Factor Activity in a Delayed

Hypersensitivity Reaction in Vivo. Fed Proc. 35:390, Apr 1976.

*11. Postlethwaite AE, Kang AH. Chemoattraction of Human Monocytes to Collagen and Collagen-derived

Peptides. Clin Res. 24:449a, Apr 1976.

*12. Postlethwaite AE, Snyderman R, Kang AH. Chemotactic Attraction of Fibroblasts to a Fragment from

the 5th Component of Complement. Arthritis Rheum. 20:131, Jan-Feb 1977.

*13. Postlethwaite AE, Seyer JM, Kang AH. Induction of Fibroblast Chemotaxis by Human Type I, II, and

III Collagens and Collagen degradation peptides. Clin Res. 25:617a, Oct 1977.

*14. Postlethwaite AE, Kang AH. Lymphokine Activation: Isolation of Latent Lymphocyte-derived

Chemotactic Factor for Monocytes (LDCF-M) and Activation by Macrophage Extract. Proceedings of the

Southeastern Arthritis and Rheumatism Meeting, Atlanta, GA, Dec 1977.

*15. Postlethwaite AE, Seyer JM, Kang AH. Chemotactic Attraction of Human Monocytes to Homologous

Type I, II and III Collagens and Collagen Degradation Peptides. Arthritis Rheum. 1978 Jun;21(5):584-5.

*16. Stuart J, Postlethwaite AE, Townes AS, Kang AH. Cell-mediated Immunity to Collagen in Rheumatoid

Arthritis. Clin Res. 27:141a, Feb 1979 and Arthritis Rheum. 22:665, Jun 1979.

*17. Postlethwaite AE. Characterization of Guinea Pig Lymphocyte-derived Chemotactic Factor for

Fibroblasts. Fed Proc. 38(3):1170, 1979.

*18. Postlethwaite AE, Keski-Oja J, Kang AH. Chemotactic Attraction of Human Fibroblasts to Fibronectin.

Clin Res. 27(4):A646, 1979.

*19. Postlethwaite AE, Kang AH. Isolation of Lymphocyte-derived Fibroblast Proliferation Factor. Clin Res.

27:749A, 1979.

*20. Ochs ME, Kang AH, Postlethwaite AE. Characterization of a Serum Inhibitory Factor for Fibroblast

Migration. Arthritis Rheum. 23(6):727a, Jul 1980.

*21. Postlethwaite AE, Kang AH. "Generation of Lymphocyte Mitogenic Factor in Vivo during a Delayed

Hypersensitivity Reaction". Fed Proc. 38(3):4688A, 1980.

*22. Postlethwaite AE, Kang AH, Snyderman R, Keski-Oj J. Fibroblast Chemoattractants. Fed Proc.

39:2746A, 1980.

*23. Jackson BK, Postlethwaite AE, Beachey EH, Kang AH. Lymphokine Induced Formation of Giant Cells

from Human Monocyte Precursors. Clin Res. 29:165A, 1981.

*24. Hibbs MS, Postlethwaite AE. Stimulation of Fibroblast Collagen Production by Allogeneic Mononuclear

Leukocytes. Clin Res. 29:559Aa, Dec 1981.

Postlethwaite CV

10/18/2016

of 26

*25. Postlethwaite AE, Kang AH. Induction of Fibroblast Proliferation by Human Lymphokines. Clin Res.

29:559A, April 1981.

*26. Hays RA, Postlethwaite AE. Evidence for a Latent Lymphokine in Man: Isolation of Latent

Lymphocyte-derived Chemotactic Factor for Monocytes (LDCF-M). Fed Proc. 40:1049, April 1981.

*27. Wyler DJ, Postlethwaite AE, Nsien E. Chemoattractant for Fibroblasts is Elaborated In Vitro by

Schistosomal Egg Granulomas. Fed Proc. 40:___, April 1981.

*28. Floyd, R, Kuo CY, Garcia M, Song A, Postlethwaite AE, Yoo TJ. Effect of Protease Inhibitors on NK

and ADCC Activities. Fed Proc. 40:1127, April 1981.

*29. Postlethwaite AE, Kang AH. Latent Lymphokines: Characterization of Guinea Pig Latent Lymphocyte-

derived Chemotactic Factor for Fibroblasts (LDCF-F). Fed Proc. 40:1048, April 1981.

*30. Postlethwaite AE, Smith GN Jr, Mainardi CL, Seyer JM, Kang AH. Characterization of a Human

Lymphokine that Stimulates Fibroblasts to Produce Collagen. Arthritis Rheum. 24(Suppl):561, April

1981.

*31. Hibbs MS, Postlethwaite AE. Stimulation of Fibroblast Collagen Production by Co-Culture with

Mononuclear Leukocytes. Arthritis Rheum. 24(Suppl):561, April 1981.

*32. Jackson BK, Postlethwaite AE, Beachey EH, Kang AH. Lymphokine-induced Fusion of Human

Monocytes to Form Multinucleated Giant Cells. Abstract #561. Arthritis Rheum. 1981 Apr;24(4

Suppl):22.

*33. Postlethwaite AE, Lachman LB, Mainardi CL, Kang AH. Stimulation of Fibroblast Collagenase

Production by Human Interleukin l. Fed Proc. 41:986, April 1982.

*34. Postlethwaite AE, Lachman LB, Kang AH. Stimulation of Fibroblast Proliferation by Interleukin l.

Arthritis Rheum. 25(Suppl):146, June 1982.

*35. Postlethwaite AE, Lachman LB, Kang AH. Stimulation of Fibroblasts Hyaluronic Acid Production by

Human Interleukin l. Arthritis Rheum. 26(Suppl):59, June 1983.

36. Hernandez AD, Reece RE, Postlethwaite AE, Marley WM, Ward ME. Basal Cell Carcinomas Regulate

In Vitro Fibroblast Function. Clin Res. 32:589A, May 1984.

37. Endres RO, Postlethwaite AE. Latent Chemotactic Factor for Fibroblast Produced by a Human T cell

Hybridoma. Fed Proc. 43(7):1996, June 1984.

38. Aelion JA, Endres RO, Postlethwaite AE. Characterization of an Interleukin-l Inhibitor Derived from

Human Synovial Fluids. Arthritis Rheum. 28:S79, June 1985.

39. Endres RO, Postlethwaite AE, Kang AH. Fibroblast Modulating Lymphokines Derived from Human T

Cell Hybridomas. Arthritis Rheum. 28:S32, June 1985.

*40. Postlethwaite AE, Kang AH. Stimulation of Fibroblast Hyaluronic Acid Production by Recombinant

Murine Interleukin-l. Clin Res. 34:221A, Feb. 1986.

*41. Postlethwaite AE, Kang AH. Stimulation of Fibroblast Collagenase Production by Recombinant Human

and Murine Interleukin-ls. Arthritis Rheum. 29:S98, June 1986.

42. Endres RO, Poppleton HM, Postlethwaite AE, Kang AH. Regulation of Human Fibroblast PGE2

Production and Proliferation of an Anti-Membrane Monoclonal Antibody. Arthritis Rheum. June 1987.

*43. Aelion JA, Postlethwaite AE, Gupta RC, Kang AH. Enhancement of Interleukin-l Co-Mitogenic

Stimulation of Thymocyte Proliferation by Sera from Patient with Progressive Systemic Sclerosis.

Arthritis Rheum. June 1987.

*44. Postlethwaite AE, Kang AH. In Vitro Models of Wound Healing: Advantages and Limitations. Second

International Symposium on Tissue Repair. May 1987.

45. Bever Jr CT, Snyder DS, Endres RO, Morgan KD, Postlethwaite AE, Whitaker JN. Activation of

Astrocytic Lysosomal Proteinases by Factors Released by Mononuclear Leukocytes. Neurochem. Res.

1988.

*46. Postlethwaite AE, Seyer JM, Kang AH. Stimulation of Monocyte Migration by Recombinant Interferon

Gamma and Interferon Gamma Peptides. Arthritis Rheum. 32 Suppl:93S, 1989.

Postlethwaite CV

10/18/2016

of 26

*47. Postlethwaite AE, Seyer JM, Kang AH. Stimulation of Fibroblast Chemotaxis by Human Recombinant

Interferon Gamma. Clin Res. 37:34A, 1989.

*48. Drake SF, Palmieri GMA, Postlethwaite AE, Massie JD, Hinton A, Miller L. Immediate Response to 3-

Amino-1-Hydroxyproline 1, 1-Bisphosphonate in a Case of Calcitonin-resistant Paget’s Disease. Clin Res.

37:36A, 1989.

*49. Postlethwaite AE, Katai H, Raghow R. Stimulation of Extracellular Matrix Biosynthesis in Fibroblasts

by Interleukin-4. Arthritis Rheum. 32 Suppl:B167, 1989.

*50. Higgins GC, Postlethwaite AE. Partial Purification of an Inhibitor of Interleukin-1 from Synovial Fluid

of Patients with Rheumatoid Arthritis. Arthritis Rheum. 32 Suppl:B46, 1989.

*51. Ballou LR Postlethwaite AE. Phospholipid Metabolism and Interleukin-1-Induced Prostaglandin E2

Production in Human Fibroblasts. Arthritis Rheum. 32 Suppl:B14, 1989.

*52. Cush JJ, Lipsky PE, Postlethwaite AE, Schrohenloher RE, Saway A, Koopman WJ. Correlation of

Serologic and Immunologic Parameters with Effectiveness of NSAID Therapy in Rheumatoid Arthritis.

Arthritis Rheum. 1989;32 (Suppl):A27.

53. Wyler DJ, Prakash S, Postlethwaite AE. Fibrosis As a Complication of Granulomatous Inflammation:

Lessons Learned From Schistosomiasis. Basic Mechanisms of Granulomatous Inflammation: Proceedings

of the International Symposium on Basic Mechanisms of Granulomatous Inflammation. ICS851,

1989:241-61.

*54. Postlethwaite AE. Human Recombinant Tumor Necrosis Factor is a Fibroblast Chemoattractant. Clin

Res. 38:478A, 1990.

*55. Postlethwaite AE. Stimulation of Fibroblast Chemotaxis by Interleukin-4. Clin Res. 38:31A, 1990.

*56. Higgins GC, Postlethwaite AE. A Synovial Fluid Inhibitor Specifically Binds IL-1. Arthritis Rheum.

33:S20, 1990.

*57. Ballou LR, Barker SC, Postlethwaite AE, Kang AH. Human Recombinant Interleukin-1 Signal

Transduction Involves Stimulated Phosphatidylinositol Kinase Activity. Arthritis Rheum. 1990.

*58. Postlethwaite AE. Stricklin GP. Modulatory Effects of Transforming Growth Factor- on Cytokine-

Induced Collagenase and TIMP Production by Fibroblasts. Clin Res. (Submitted to the 1991 Southern SCI

Meeting).

*59. Postlethwaite AE, Seyer JM, Ballou LR. Oligopeptides from the Propeptide Portion of Human IL-1

Possess Proinflammatory Activities. Arthritis Rheum. 34(9):85, 1991.

*60. Postlethwaite AE, Seyer JM. Mapping of IL-1 Receptor Binding Epitopes on Human IL-1 and by Use

of Synthetic IL-1 Oligopeptides. Arthritis Rheum. 34(9):C133, 1991.

*61. Postlethwaite AE, Seyer JM. Identification of Fibroblast Mitogenic Epitopes on Human IL-1 and by

Use of Synthetic IL-1 Oligopeptides. Arthritis Rheum. 34(9):C132, 1991.

*62. Postlethwaite AE, Seyer JM. Identification of Monocyte Chemotactic Epitopes on Human IL-1.

Arthritis Rheum. 34(9):C143, 1991.

*63. Postlethwaite AE. IL-4 Stimulation of Production of Hyaluronic Acid by Fibroblasts: Synergism with

IL-1. Clin Res. 1992.

*64. Postlethwaite AE, Sampath TK, Raghow R. Stimulation of Neutrophil, Monocyte, and Fibroblast

Chemotaxis by Osteoinductive Protein-1. Arthritis Rheum. 35(Suppl):PO188, 1992.

65. Higgins GC, Foster JL, Postlethwaite AE. Synthesis and Biological Activity of Human IL-1 Propiece

In Vitro. Arthritis Rheum. 36 (Suppl):B71, 1993.

*66. Postlethwaite AE, Seyer JM, Armendariz J. Stimulation of Elevated Levels of IL-1 Protein and IL-1

mRNA by Synthetic TGF-1 Peptide 337-374. Arthritis Rheum. 36(Suppl):B79, 1993.

*67. Postlethwaite AE, Seyer JM, Stricklin G, Ballou LR, Higgins G. Synthetic Peptides Representing Human

IL-11-112 Profragment Regulate Fibroblast Function. Arthritis Rheum. 36(Suppl):B80, 1993.

*68. Postlethwaite AE, Ballou LR. Regulation of Fibroblast Cytokine Production by PGE2. Clin Res. 1994.

Postlethwaite CV

10/18/2016

of 26

69. McKown KM, Carbone LD, Kaplan SB, Aelion JA, Lohr KM, Cremer MA, Bustillo J, Gonzalez M,

Kaeley G, Seyer JM, Kang AH, Postlethwaite AE. Oral Bovine Type II Collagen Added to Existing

Therapy in Rheumatoid Arthritis is not Efficacious. Arthritis Rheum. 40:S195, 1997.

70. Postlethwaite AE, Kang AH, Myers LK. NSAIDs Abrogate Oral Tolerance Induction to Type II Collagen

in DBA/1 Mice. Arthritis Rheum. 40:S54, 1997.

71. McKown KM, Carbone LD, Bustillo J, Seyer JM, Kang AH, Postlethwaite AE. Open Trial or Oral Type

I Collagen in Patients with Systemic Sclerosis (SSc). Arthritis Rheum. 40:S100, 1997.

72. Higgins GC, Postlethwaite AE. Intracellular Precursor IL-1 Regulates Intracellular IL-1 Receptor

Antagonist in Human Dermal Fibroblasts. Arthritis Rheum. 40:S180, 1997.

*73. Postlethwaite AE, Higgins GC, Foster J, Seyer JM. Human Recombinant IL-1 28-116 Propeptide

Induces Monocyte Chemotaxis: Identification of the Chemotactic Epitopes Spanning Amino Acid

Residues 58-87 and 86-116. Arthritis Rheum. 40:S222, 1997.

*74. Postlethwaite AE, McKown, K, Seyer, JM, Kang AH. Type I Collagen (CI) Epitope Recognition by SSc

Peripheral Blood Mononuclear Cells (PBMC). Arthritis Rheum. 1998.

*75. Postlethwaite AE, Wheller P, Myers LK, Kang AH. PGE1 Analog (Misoprostol) Reverses NSAID

Mediated Oral Tolerance (OT) Inhibition. Arthritis Rheum. 1998.

*76. Postlethwaite AE, Land M, Ingels J, Pifer L, Palmieri G. Pamidronate Modulates Peripheral Blood

Mononuclear Cell Cytokines in AIDS and HIV Positive Patients. ASBMR-IBMS Second Joint Meeting,

San Francisco, CA, December 5, 1998.

*77. Myers LK, Higgins G, Thomson J, Walton C, Hendricks J, Kerr N, Pandya R, Shlopov B, Seyer JM,

Postlethwaite AE, Kang AH. Oral type II collagen in JRA. J Invest Med 1999(47):2. Conference paper.

*78. Wang B, Sun Y, Postlethwaite AE, Weber KT, Kiani MF. Neovasculature in Bone Marrow Stem Cell

Mobilization for Treating Myocardial Infarction. Annual International Conference of the IEEE

Engineering in Medicine and Biology – Proceedings 2002;1(748-9). Conference paper.

79. Holt MM, Postlethwaite AE, Ingels JF, Gerling IC, Weber KT. Angiotensin II-Induced Modulation of

Tumor Necrosis Factor-Alpha Production by Human Peripheral Blood Mononuclear Cells. J Investig

Med. 2003;51(Suppl 1):S259.

80. Holt MM, Postlethwaite AE, Ingels JF, Gerling IC, Weber KT. Tumor Necrosis Factor-A Production by

Human Peripheral Blood Mononuclear Cells. Response to Angiotensin II. J Mol Cell Cardiol.

2003;35:A21.

81. Schwender FT, Wang B, Sun Y, Postlethwaite AE, Weber KT, Kiani MF. Neovasculature of the Infarct

Scar: Need to Expand Angiogenic and Vasculogenic Components. J Am Coll Cardiol. 41(Suppl A):394A,

2003.

82. Malhotra A, Gerling IC, Sun Y, Warrington KJ, Postlethwaite AE, Weber KT. Aldosterone Receptor

Antagonism as Immunomodulatory Therapy in Aldosteronism. Circulation 108(Suppl IV):IV-195, 2003.

*83. Postlethwaite AE, Wong WK, Ingels J, Kang AH, Clements P, Furst DE, Oral CI/SSc Study

Investigators. Correlations between Clinical Measurement in Systemic Sclerosis (SSc) and Immune

Response to Type I Collagen (CI). Presented at the Annual American College of Rheumatology Meeting,

Orlando, FL, October 2003.

84. Wodi LA, Ahokas RA, Warrington KJ, Gerling IC, Sun Y, Bhattacharya SK, Postlethwaite AE, Weber

KT. The proinflammatory coronary vascular phenotype of aldosteronism: role of cytosolic free [Mg2+]i

and [Ca2+]i in peripheral blood mononuclear cell activation. J Investig Med. 2004;52 (Suppl 1):S264.

*85. Postlethwaite AE, Wheller PA, Weisfeld D. Selective COX-1 Inhibition Does Not Block Oral Tolerance

(OT). Presented to the American Federation for Medical Research Southern Society Meetings, New

Orleans, February 2004. J Invest Med 52: S305, 2004.

Postlethwaite CV

10/18/2016

of 26

*86. Postlethwaite AE, Wong WK, Ingels J, Kang AH, Clements P, Furst DE, and Oral CI/SSc Study

Investigators. Correlations between Clinical Measurement in Systemic Sclerosis (SSc) and Immune

Response to Type I Collagen (CI). Presented to the American Federation for Medical Research Southern

Society Meetings, New Orleans, February 2004. J Invest Med 52: S286, 2004.

87. Postlethwaite AE, Wong WK, Ingels J, Kang AH, Clements P, Furst DE, and Oral CI/SSc Study

Investigators. Increased Outgrowth of Fibroblast-Like Cells (FLC) from SSc Collagen Stimulated

Peripheral Blood Mononuclear Cells (PBMC) is Associated with Decreased Lung Carbon Monoxide

Diffusion Capacity (DLCO). American College of Rheumatology, 2004.

88. Postlethwaite AE, Ingels J. Interferon Gamma (IFN) Promotes Transdifferentiation of Blood

Mononuclear Cells into Fibroblast Like Cells (FLC). American College of Rheumatology, 2004.

89. Postlethwaite AE, Carbone L, McKown K, Kanangat S, Kang AH, Ingels J. Transdifferentiation of

Fibroblast-Like Cells (FLC) from Monocyte Precursors from Peripheral Blood of Patients with Systemic

Sclerosis (SSc). American College of Rheumatology, 2004.

90. Chhokar VS, Bhattacharya SK, Ahokas RA, Martinez A, Postlethwaite AE, Sun Y, Weber KT.

Oxi/nitrosative stress and bone loss in aldosteronism. J Mol Cell Cardiol. 2004;36:627.

*90. Postlethwaite AE, Seyer JM, Endres R, Ward F, Kang AH, Myers L, McKown K, Barrow K, Carbone L.

HLA Associations with T Cell Reactivity To Type II Collagen (CII) Epitopes in Patients with Rheumatoid

Arthritis (Ra). American Federation for Medical Research Southern Society Meeting, New Orleans,

February 2005.

91. Warrington KL, Carbone LD, Nair U, Kang AH, Postlethwaite AE. Antifibrogenic Cells in Scleroderma.

American Federation for Medical Research Southern Society Meeting, New Orleans, February 2005.

92. Postlethwaite AE, Seyer JM, Endres R, Ward F, Kang AH, Myers L, McKown K, Barrow K, Carbone L.

HLA Associations with T Cell Reactivity To Type II Collagen (CII) Epitopes in Patients with Rheumatoid

Arthritis (RA). Submitted to the American College of Rheumatology, 2005.

93. Postlethwaite AE, Wong WK, Ingels J, Kang AH, Clements P, Furst DE, Oral CI/SSc Study

Investigators. Maximal T Cell Reactivity to Type I Collagen (CI) is Present during the First 3 Years of

Diffuse Systemic Sclerosis (SSc). American College of Rheumatology, 2005.

94. Warrington KJ, Carbone LD, Barrow KD, Pugazhenthi M, Watsky MA, Somes G, Ingles J, Postlethwaite

AE. Lymphocyte Activation and Upregulation of Anti-Fibrotic Cytokines by Pamidronate Treatment of

Patients with Limited or Diffuse Scleroderma. American College of Rheumatology Annual Meeting, San

Francisco, California, 2005. (Arthritis Rheum. 2005;52(Suppl 9): S283)

95. Watsky MA, Yin Z, Carbone LD, Postlethwaite AE. An LPA-Activated Cl- Current (IClLPA) in

Myofibroblasts from Scleroderma Patients. FASEB Summer Conference on Lysophospholipid Mediators

in Health and Disease. Snowmass Village, CO, June 11-16, 2005.

96. Khanna D, Hays RD, Furst DE, Wong WK, Tsevat JT, Clements PJ, Park GS, Ahmed M, Postlethwaite

AE, Collagen Study Group. Assessment of SF-6D, A Preference Measure, In Systemic Sclerosis. Abstract

#770. 70th Annual Meeting of the American College of Rheumatology, Washington, DC, November 10-

15, 2006. Ann Rheum Dis 2006 Mar 15.

97. Postlethwaite AE, Wong WK, Furst DE, Clements P, Kang AH, Investigators of the SSc Phase II Oral

CI Clinical Trial. Oral Type I Collagen (CI) Treatment of Diffuse Systemic Sclerosis (SSc) Patients

Induces Different Immune Responses to CI Cyanogen Bromide (CB) Peptides in Early Phase Patients

(EPP) and Late Phase Patients (LLP). 71st Annual Meeting of the American College of

Rheumatology/ARHP, Boston, MA, November 6-11, 2007.

98. Kanangat S, Hasty KA, Park H, Woods S, Appling W, Kang AH, Postlethwaite AE. Involvement of IC-

IL-1RA in the Transition of Low Density Seeded Fibroblasts into Myofibroblasts. Abstract #67. 71st

Annual Meeting of the American College of Rheumatology/ARHP, Boston, MA, November 6-11, 2007.

Postlethwaite CV

10/18/2016

of 26

99. Postlethwaite AE, Kang AH, Carbone LD, Seyer JM, Endres R, Ward F. HLA Associations with T Cell

Reactivity to Type II Collagen (CII) Epitopes in Patients with Rheumatoid Arthritis (RA). Abstract #1047.

71st Annual Meeting of the American College of Rheumatology/ARHP, Boston, MA, November 6-11,

2007.

100. Amjadi S, Maranian P, Furst D, Clements P, Wong W, Seibold J, Postlethwaite A, Khanna D. Course of

Modified Rodnan Skin Score in Systemic Sclerosis Clinical Trials: Analysis of 3 Large Multicenter,

Randomized Clinical Trials. Abstract #545. 72nd Annual Meeting of the American College of

Rheumatology/ARHP, San Francisco, CA, October 24-29, 2008.

*101. Postlethwaite AE, Wong WK, Clements P, Kang AH, Ingels J, Furst DE, Investigators of the SSc Phase

II Oral CI Clinical Trial. Patients with Diffuse Cutaneous Systemic Sclerosis (dc SSc) Treated with Oral

Type I Collagen (CI) Who Experienced ≥25% Improvement in Modified Rodman Skin Score (mRSS)

Upregulated IL-10 Production to Specific Cyanogen Bromide (CB) Fragments of CI. Abstract 475. (Poster

presentation) 73rd Annual Meeting of the American College of Rheumatology/ARHP, Philadelphia, PA,

October 16-19, 2009. (Arthritis Rheum 2009 Oct;60(supp10):475. doi: 10.1002/art.25557.

102. Brown M, Postlethwaite AE, Myers LK, Hasty K. Cytokines Produced by Type I Collagen (CI)-

Stimulated PBMC From Patients with Systemic Sclerosis (SSc) but Not Localized Scleroderma (LS)

Inhibit Matrix Metalloproteinase (MMP-1) Expression in SSc Dermal Fibroblasts. Abstract #1809. (Poster

presentation) 72nd Annual Meeting of the American College of Rheumatology/ARHP, Philadelphia, PA,

October 16-19, 2009. (Arthritis Rheum 2009 Oct;60(supp10):1809. doi: 10.1002/art.26883.

103. Wang J, Slominski A, Tuckey R, Janjetovic Z, Kulkarni A, Chen J, Postlethwaite A, Miller D, Li W. 20-

Hydroxyvitamin D3 Possesses High Efficacy Against Proliferation of Cancer Cells While Being Non-

Toxic. Abstract 8/Poster #690. Society for Investigative Dermatology, Raleigh, NC, May 9-12, 2012. [JID

2012;132(S149-S173). doi:10.1038/jid.2012.89]

104. Myers LK, Postlethwaite AE, Li W, Miller DD, Tuckey RC, Slominski A. Noncalcemic Natural Vitamin

D Analog, 20(OH)D3, Enhances Immunosuppressive Properties of an Altered Peptide Ligand. Abstract

573. Society for Investigative Dermatology, Raleigh, NC, May 9-12, 2012. [JID 2012;132(S149-S173).

doi:10.1038/jid.2012.89].

105. Kim S, Tang B, Hammond S, Cullins DL, Brand D, Rosloniec EF, Stuart JM, Postlethwaite AE, Kang

AH, Myers L. Characterization of T Cell Phenotype and Function in a Double Transgenic (Collagen-

Specific TCR/HLA-DR1) Humanized Model of Arthritis. Abstract #1654. 77th Annual Meeting of the

American College of Rheumatology/Association of Rheumatology Health Professionals, San Diego, CA,

October 25-30, 2013.

106. Brown Lobbins ML, Slominski A, Hasty K, Miller D, Li W, Kim T-K, Tuckey RC, Postlethwaite AE.

Modulation by 17,20R(OH)S2pD of Fibrosis-related Mediators: Studies in Dermal Fibroblast Lines from

Healthy Donors and from Patients with Systemic Sclerosis. Poster presentation, 2016 National Patient

Education Conference: Unmask the Cure. Scleroderma Foundation, New Orleans, LA, July 29-30, 2016

*Presented

Postlethwaite CV

10/18/2016

of 26

Community/Professional Service/Lectures

1. Advisory Board, Tennessee Chapter of the National Scleroderma Foundation, 2000-Present.

2. Grand Rounds: “Scleroderma”, College of Medicine, The University of Tennessee Health Science Center,

Memphis, TN, August 27, 2008.

3. Grand Rounds: “Things Vitamin D Does in Addition to Affecting Calcium and Bone Metabolism”. College

of Medicine, The University of Tennessee Health Science Center, Memphis, TN, April 4, 2012.

http://mediaserver.uthsc.edu/uthscms/Play/dab1e09d81f140589f16064f0cee67601d

4. “The Role of Vitamin D in Autoimmune and Fibrotic Disease.” Workshop at the 2012 National Patient

Education Conference of the Scleroderma Foundation, Grapevine, Texas, July 27-29, 2012.

5. “Meaningful Use: Noncalcemic Vitamin D Analogs.” Speaker, 2013 Tennessee Rheumatology Society

Annual CME Meeting, Nashville, Tennessee, February 16, 2013.

6. “Naturally Occurring Noncalcemic Analogs of Vitamin D Possess Immunomodulatory and Anti-Fibrotic

Properties.” 2nd Spring Immunology Symposium: Immunologic Diseases & Basic Immunology. University

of Alabama at Birmingham, AL, June 21-23, 2013.

7. “Sleep Disturbance in Scleroderma” and “Platelets: The Rodney Dangerfield of Scleroderma.” Workshops at

the Scleroderma Foundation 2013 National Patient Education Conference, “Knock Out Scleroderma-Fifteen

Years of Fighting”, Atlanta, GA, July 26-28, 2013.

8. Grand Rounds: “Consequences of Chronically Disregulated Sleep”, College of Medicine, The University of

Tennessee Health Science Center, Memphis, TN, March 11, 2014.

9. “Are Endogenous or Marijuana-Derived Cannabinoids Potential Therapeutics for Scleroderma?”

(https://www.youtube.com/watch?v=a_Uklp49aCM) and “The Brain and Brain Function in Scleroderma”.

Workshops at the Scleroderma Foundation 2014 National Patient Education Conference, “Join the Cause –

Believe in a Cure,” Anaheim, CA, July 25-27, 2014.

10. “The Brain and Brain Function in Scleroderma”. Workshop at Tri-State Chapter of the Scleroderma

Foundation, New York, NY, April 22-25, 2015.

11. Workshops: “The Human Microbiome and How It May Affect Scleroderma”, and “Statins, Mostly Good but

Can Sometimes be Bad and Ugly”. 2015 Scleroderma Foundation National Patient Education Conference:

Stomping Out Scleroderma, Nashville, TN, July 17-19, 2015.

12. Grand Rounds, How Statins Really Work: “Statins, The Good, the Bad, and the Ugly: A Rheumatologist’s

Perspective”. College of Medicine, The University of Tennessee Health Science Center, Memphis, TN,

October 21, 2015.

13. Workshops: “Can I or Should I Eat This?”, and “Dietary Supplements in Scleroderma”. 2016 18th Annual

Scleroderma Foundation National Patient Education Conference: Unmask the Cure, New Orleans, LA, July

29-31, 2016.

Publicity

1. Postlethwaite AE. “Understanding Arthritis and Management” Tennessee Tribune, March 2016.

www.tntribune.com.

http://mediaserver.uthsc.edu/uthscms/Play/dab1e09d81f140589f16064f0cee67601d

https://www.youtube.com/watch?v=a_Uklp49aCM

http://www.tntribune.com/

Arnold Eugene Postlethwaite, MD, AB...1966-1967 Medicine Internship, Tulane Division, Charity...

Documents

Transcript of Arnold Eugene Postlethwaite, MD, AB...1966-1967 Medicine Internship, Tulane Division, Charity...